<DOC>
	<DOCNO>NCT01913639</DOCNO>
	<brief_summary>The purpose study evaluate effect , good and/or bad , drug regorafenib chemotherapy regime ( FOLFOX ) . This Phase II trial study new treatment effective safe patient esophagus stomach cancer .</brief_summary>
	<brief_title>FOLFOX Plus Regorafenib Patients With Unresectable Metastatic Esophagogastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patient must histologically cytologically confirm metastatic unresectable esophageal , gastroesophageal junction gastric adenocarcinoma . Patient must disease evaluate radiographically . This may measurable disease nonmeasurable disease . Minimum indicator lesion size = 10 mm helical CT = 20 mm conventional technique . Pathological node must = 15 mm short axis consider measurable . Subject must able swallow retain oral medication Age 18 year old . Karnofsky performance status &gt; = 70 % Peripheral neuropathy ≤ grade 1 Hematologic ( minimal value ) White blood cell count &gt; = 3000/mm3© Absolute neutrophil count &gt; 1500 cells/ mm3 Hemoglobin &gt; = 8.0 g/dl Platelet count &gt; = 90,000 / mm3 Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) Alkaline phosphatase limit ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) . Patients alkaline phosphatase elevation secondary bony metastasis rather liver dysfunction may proceed treatment protocol discussion principal investigator . Serum creatinine ≤ 1.5 x ULN Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test.. Patients prior deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) currently stable anticoagulation regimen low molecular weight heparin ( LMWH ) rivaroxaban permit . Uncontrolled hypertension ( systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg repeat measurement ) despite optimal medical management . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II . Active coronary artery disease . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . Evidence history bleed diathesis coagulopathy . Any hemorrhage bleeding event ≥ NCI CTCAE version 4.0 Grade 3 within 4 week prior start study medication . Unwillingness give write informed consent , unwillingness participate , inability comply protocol duration study . Active hepatitis B infection , active hepatitis C infection know HIV carrier . Patient may receive prior chemotherapy metastatic unresectable disease . Patients may receive prior adjuvant therapy ( chemotherapy and/or chemoradiation ) 6 month elapse end adjuvant therapy registration . Patient may receive prior 5Fluorouracil , Leucovorin , Oxaliplatin regorafenib . Patient may receive prior radiosensitizing dos 5Fu 6 month elapse end adjuvant therapy registration . Patient may major surgical procedure within 4 week registration . Patient may radiation within 2 week registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>BAY 73-4506 ( REGORAFENIB )</keyword>
	<keyword>FLUOROURACIL</keyword>
	<keyword>LEUCOVORIN</keyword>
	<keyword>OXALIPLATIN</keyword>
</DOC>